Response, toxicity, and survival.

(A) Response rates and grade 3 toxicities; (B) EFS and OS. (C) EFS and (D) OS according to the number of unfavorable prognostic factors present prior to thalidomide. Risk discrimination on the basis of abnormal CG (EFS hazard ratio [HR] 2.15,P < .001; OS HR 2.53, P = .002); plasma cell labeling index (PCLI) greater than 0.5% (EFS HR 1.86,P = .002; OS HR 1.82, P = .009); and B2M greater than 3 mg/L (EFS HR 1.54, P = .016; OS HR 2.99,P < .001). Solid lines indicate no risk factors; dashed line, 1; dotted line, 2; and dash-dotted line, 3 risk factors. Additional unfavorable variables that are only univariately significant included the following for EFS: albumin level less than 3.5 g/dL,P = .003; and BM plasmacytosis greater than 30%,P = .001. Additional unfavorable variables that are only univariately significant included the following for OS: albumin level less than 3.5 g/dL, P < .001; BM plasmacytosis greater than 30%, P = .05; hemoglobin level less than 10 g/dL,P < .001; creatinine greater than 1.5 mg/dL,P < .001; and platelet count fewer than 100 000 μL, P = .007. TRM indicates treatment-related mortality; DVT, deep veinous thrombosis.